Microbix Biosystems Inc.

MBX.TOTSXHealthcare● Active

$0.28

+$0.01(+3.70%)

Market Cap$38794840

P/E Ratio—

52W High$0.34

52W Low$0.21

Avg Volume59K

Open$0.28

Beta0.57

Free Cash Flow Financials Revenue

Microbix Biosystems Inc. (MBX.TO) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

MBX.TO · free cash flow · updated Jun 9, 2026

Core FCF metrics

MBX.TO · FCF · TTM · margin & CAGR

Free cash flow was −$877,580 for FY2025 (fiscal year ending 2025-09-30), down 136.0% year-over-year The FCF margin was -4.7%.

FY2025 Free Cash Flow−$877,580▼ -136.0% YoY

Trailing 12M (TTM)−$5.5Mtrailing 4 quarters sum

FCF Margin-4.7%−$877,580 ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

MBX.TO · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$80,287(1M)−$877,580▼ 136.0%-4.7%

FY2024$4.3M(2M)$2.4M▲ +215.6%9.6%

FY2023−$1.1M(1M)−$2.1M▼ 246.6%-12.8%

FY2022$3.5M(2M)$1.4M▲ +79.0%7.5%

FY2021$2.1M(1M)$804,197▲ +199.9%4.3%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

MBX.TO · P/FCF · FCF yield · FCF per share

Microbix Biosystems Inc. (MBX.TO) reported negative free cash flow of −$0.00B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-09-30

Cash flow statement summary

MBX.TO · cash flow statement · operating / investing / financing

For FY2025, Microbix Biosystems Inc. generated −$0.1M in operating cash flow and spent 1M in capital expenditures, yielding −$0.9M in free cash flow.

Operating Activities

−$0.1M

Cash from core business operations

2025-09-30

Investing Activities

−$0.8M

CapEx, acquisitions & investments

2025-09-30

Financing Activities

+$0.0M

Buybacks, dividends & debt

2025-09-30

FCF FormulaOperating CF (−$0.1M) − |CapEx| (1M) = FCF (−$0.9M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

MBX.TO vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Microbix Biosystems Inc.YOU

MBX.TO

−$877,580-136.0%-4.7%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Microbix Biosystems Inc. (MBX.TO) reported free cash flow of −$877,580 for FY2025 (fiscal year ending 2025-09-30), down 136.0% year-over-year. The FCF margin was -4.7%.

Based on available data, Microbix Biosystems Inc. has maintained positive free cash flow for at least 4 fiscal year(s). FCF peaked at $2.4M in FY2024.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

MBX.TO free cash flow · 8 questions

Microbix Biosystems Inc. free cash flow was −$877,580 for FY2025, down 136.0% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$5.5M.

MBX.TO free cash flowMBX.TO FCFMBX.TO FCF 2025MBX.TO free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Microbix Biosystems Inc. · Microbix Biosystems Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026